XORTX Therapeutics Inc.
XRTX
$0.87
-$0.1026-10.55%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.23% | 5.50% | -9.19% | -0.77% | 8.71% |
| Depreciation & Amortization | 56.97% | 3.13% | -51.95% | 7.96% | -25.34% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.32% | -37.26% | -63.12% | -72.40% | -43.84% |
| Operating Income | 45.32% | 37.26% | 63.12% | 72.40% | 43.84% |
| Income Before Tax | 55.98% | 110.05% | -64.79% | 204.65% | -11.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 55.98% | 110.05% | -64.79% | 204.65% | -11.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.98% | 110.05% | -64.79% | 204.65% | -11.38% |
| EBIT | 45.32% | 37.26% | 63.12% | 72.40% | 43.84% |
| EBITDA | 45.42% | 39.14% | 62.44% | 72.67% | 44.04% |
| EPS Basic | 69.69% | 106.92% | -30.88% | 183.23% | 19.58% |
| Normalized Basic EPS | 69.68% | 106.92% | -30.89% | 183.22% | 19.58% |
| EPS Diluted | 69.82% | 106.89% | -30.81% | 182.68% | 19.28% |
| Normalized Diluted EPS | 69.68% | 106.92% | -30.89% | 183.22% | 19.58% |
| Average Basic Shares Outstanding | 45.27% | 45.27% | 25.91% | 25.74% | 38.49% |
| Average Diluted Shares Outstanding | 45.27% | 45.27% | 25.91% | 25.74% | 38.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
